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Objectives: The aim was to assess the performance of antigen-based rapid diagnostic tests (Ag-RDTs) for
SARS CoV-2 when implemented for large-scale universal screening of asymptomatic individuals.
Methods: This study was a pragmatic implementation study for universal Ag-RDT-based screening at a
tertiary care hospital in Germany where patients presenting for elective procedures and selected
personnel without symptoms suggestive of SARS-CoV-2 were screened with an Ag-RDT since October
2020. Test performance was calculated on an individual patient level.
Results: In total, 49 542 RDTs were performed in 27 421 asymptomatic individuals over a duration of 5
and a half months. Out of 222 positive results, 196 underwent in-house confirmatory testing with PCR,
out of which 170 were confirmed positive, indicating a positive predictive value of 86.7% (95% CI 81.2
e91.1%). Negative Ag-RDTs were not routinely tested with PCR, but a total of 94 cases of false negative
Ag-RDTs were detected due to PCR tests being performed within the following 5 days with a median
cycle threshold value of 33 (IQR 29e35).
Discussion: This study provides evidence that Ag-RDTs can have a high diagnostic yield for transmission
relevant infections with limited false positives when utilized at the point of care on asymptomatic pa-
tients and thus can be a suitable public health test for universal screening. Jonas Wachinger, Clin
Microbiol Infect 2021;▪:1
© 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology
and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Several researchers and policy makers, supported by evidence
from modelling studies, have recently argued to increase large-
scale screening for SARS-CoV-2 to curb transmission from pa-
tients with minimal or no symptoms [1e5]. Antigen detection
point-of-care rapid diagnostic tests (Ag-RDTs) have shown very
good sensitivity (88%) in persons with high viral load (cycle
threshold (CT) < 30) along with high specificity (>99%) [6,7].
With their favourable ease of use, rapid turnaround and good
(although suboptimal) performance, Ag-RDTs meet the charac-
teristics for a test for public health use and could allow for betterter of Infectious Diseases, Heidelbe
.de (C.M. Denkinger).
r Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).
., The potential of SARS-CoV-
doi.org/10.1016/j.cmi.2021.07control of transmission if implemented in well-designed uni-
versal screening strategies [8,9]. However, one frequently raised
concern has been the potentially imperfect specificity, leading to
large numbers of false positives when using Ag-RDTs in large-
scale screening strategies with low prevalence [10], which
could conceivably disrupt workflows and undermine trust in the
test. Furthermore, in a setting where high-risk persons are pre-
sent (e.g., hospital), concerns exist regarding imperfect sensi-
tivity leading to secondary cases and substantial morbidity and
mortality. Data from large-scale screening implementation ef-
forts that would allow to gauge diagnostic yield and issues with
false positives are limited.rg University Hospital, Im Neuenheimer Feld 324, 69120, Heidelberg, Germany.
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We performed a large-scale, pragmatic implementation study of
Ag-RDTs in the context of a universal screening programme at one
of Germany's largest tertiary care hospitals (Heidelberg University
Hospital, Germany) serving over 100 000 inpatients and 1.3 million
outpatients per year [11]. The study was conducted between 20
September 2020 and 7 March 2021 during Germany's second wave
of COVID-19. Over the duration of the study, SARS-CoV-2 incidence
in the region served by the hospital ranged from 11.6 cases per
100 000 inhabitants in the last 7 days (23 September) to 254.2 (22
December) [12]. Patients without SARS-CoV-2-associated symp-
toms presenting for elective procedures, including outpatient
treatment requiring close contact or longer presence (e.g., dialysis),
were screened with an Ag-RDT. Additionally, depending on setting
and local SARS-CoV-2 infection dynamics, other external personnel
(e.g., craftspeople, visitors, translators) were similarly screened. The
test usedwas the STANDARDQ COVID-19 Ag Test (SD Biosensor, Inc.
Gyeonggi-do, Korea), a WHO recommended and independently
validated instrument-free lateral flow assay for SARS-CoV-2
detection [13e15] performed at point of care using the nasopha-
ryngeal swabs provided in the kit. Prior to screening initiation,
nursing staff were trained to perform the test and had to pass a
competency test implemented by members of the hospital hygiene
department. In patients with a positive Ag-RDT, an additional
nasopharyngeal swab was collected for confirmatory SARS-CoV-2
PCR using one of the following commercially available PCRs: the
SARS CoV-2 assay from TibMolbiol (Berlin, Germany), the Allplex
SARS-CoV-2 Assay from Seegene (Seoul, South Korea) or the Abbott
(Illinois, USA) RealTime 2019-nCoV assay. Ag-RDT results were
confirmed with PCR in selected departments (e.g., haematology)
prior to ward admission, prior to planned procedures associated
with high levels of aerosol production, when a patient developed
SARS-CoV-2 associated symptoms, or for contact screening when a
case was detected on hospital wards. To analyse diagnostic yield of
Ag-RDTs and false positives, we systematically extracted results of
the Ag-RDTs performed from the hospital internal laboratory sys-
tem, as well as results of PCR tests (with CT values) that were done
within 5 days after Ag-RDT screening. Positive predictive value
(PPV), sensitivity, and 95% confidence intervals were computed
using the confirmatory PCR result as the reference standard.Fig. 1. SARS-CoV-2 PCR CT-values according to Ag-RDT result (left) and for false-negative A
panel: CT values were higher among patients with negative versus positive RDTs (p < 0.001)
not differ between the different groups (p ¼ 0.339).
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correlated, sensitivity and predictive values were calculated on
individual patient rather than test level. Analysis was conducted
using R v4.0.3 (The R Foundation). The ethics review board at
Heidelberg University approved this study (S-811/2020).
Results
Between 20 September 2020 and 7March 2021, 49 542 Ag-RDTs
were performed in 27 421 asymptomatic individuals. Of the total
27421 patients tested, 19 712 (72%) were only tested once. Ag-RDTs
were positive in 222 individuals and 49 320 Ag-RDTs were negative
in 27 199 individuals. Out of the 222 individuals with positive Ag-
RDTs, 196 (88.3%) were also tested using PCR in-house. The PPV
for the Ag-RDTs was 170/196 (86.7%, 95% CI 81.2e91.1%). Among
patients with a positive confirmatory PCR performed within 5 days
of a positive Ag-RDT, the median CT value was 19 (interquartile
range, IQR 15e24, Fig. 1). Additionally, 7165 PCRs were negative
within 5 days of a negative RDT.
Of 27421 patients with a negative Ag-RDT, 94 had a positive PCR
in the 5 days following the Ag-RDT. The median number of days
between the tests was 1 (IQR 0e1). Based on these false-negative
cases identified via PCR, the overall sensitivity of the Ag-RDT can
be estimated to be 170/264 (64.4%, 95% CI 58.3e70.2). The median
CT value of patients who were missed using Ag-RDTs was 33 (IQR
29e35). In total, only 12/94 (12.8%) Ag-RDT false-negative patients
had a PCR with a CT value < 25, and 10/12 were identified on the
same or following day.
Discussion
This pragmatic implementation study of a universal screening
programme of asymptomatic patients at a tertiary care hospital
where quick turnaround and detection of cases with high risk of
secondary transmission were essential showed the benefit of Ag-
RDTs identifying SARS-CoV-2-infected persons who would have
otherwise entered a high-risk environment leading to potential
secondary transmission. The sensitivity estimated in this study is
higher than that observed in other studies of asymptomatic in-
fections [7]. Although the data on accuracy in asymptomatic pa-
tients is limited, we acknowledge that the sensitivity estimate isg-RDT results according to the number of days between discordant tests (right). Left
. Right panel: among patients with a negative RDT and a positive PCR, the CT values did
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asymptomatic infections were PCR tested in this pragmatic study.
However, as viral load kinetics have been confirmed to be largely
similar in asymptomatic and symptomatic patients, judging from
performance in symptomatic patients, one would expect to capture
most infections in the first week of illness in asymptomatic persons
when viral load is high and thus prevent most secondary trans-
missions [7,16,17]. This is supported by the few new cases observed
in the hospital during the study period. The imperfect sensitivity
however highlights the need for the continuation of other protec-
tive measures. Furthermore, authorities have recommended
against clinical extrapolation of infectiousness based exclusively on
CT [18]. Missed cases with CT < 25 on PCR testing were identified
within 24 hours and are likely attributable to a negative Ag-RDT in
the early phase of disease when the viral load is increasing rapidly
[19]. Our study also showed a very high PPV of the Ag-RDT, thus
confirming the high reliability of a positive result from an Ag-RDT
shown in accuracy studies [7].
To the best of our knowledge, this is the first large-scale
implementation study of a universal screening programme of
asymptomatic individuals to analyse the diagnostic yield of SARS-
CoV-2 Ag-RDTs. The central limitation of this study, inherent to a
pragmatic implementation study, is the limited confirmatory PCR
testing for negative Ag-RDTs, and potential selection bias associ-
atedwith confirmatory testing being only performed in high-risk or
subsequently symptomatic patients. Additionally, the delay in
confirmatory PCR-based testing merits caution when interpreting
the sensitivity and specificity estimates.
In conclusion, this study provides evidence that an Ag-RDT can
be a suitable test for large-scale universal screening in a hospital
setting and adds the important component of a public health test to
our diagnostic armamentarium. Even as vaccination rates continue
to increase, given the emergence of novel virus variants, resulting
immune escape despite vaccination, and the high risk associated
with undetected infections in clinical settings, we expect universal
screening to remain necessary as the pandemic progresses.
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